Equities analysts expect IRIDEX Co. (NASDAQ:IRIX) to announce earnings per share (EPS) of ($0.18) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for IRIDEX’s earnings, with the highest EPS estimate coming in at ($0.16) and the lowest estimate coming in at ($0.19). IRIDEX posted earnings per share of ($0.26) in the same quarter last year, which suggests a positive year over year growth rate of 30.8%. The firm is expected to issue its next earnings report on Thursday, November 7th.

According to Zacks, analysts expect that IRIDEX will report full-year earnings of ($0.74) per share for the current fiscal year, with EPS estimates ranging from ($0.78) to ($0.70). For the next year, analysts expect that the business will report earnings of ($0.46) per share, with EPS estimates ranging from ($0.50) to ($0.41). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for IRIDEX.

IRIDEX (NASDAQ:IRIX) last released its earnings results on Tuesday, August 6th. The medical equipment provider reported ($0.18) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.22) by $0.04. The firm had revenue of $10.43 million during the quarter, compared to analyst estimates of $10.94 million. IRIDEX had a negative return on equity of 39.42% and a negative net margin of 26.02%.

Several brokerages have commented on IRIX. ValuEngine upgraded IRIDEX from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Zacks Investment Research upgraded IRIDEX from a “hold” rating to a “strong-buy” rating and set a $3.25 price target for the company in a research note on Saturday.

Large investors have recently made changes to their positions in the business. Gabelli Funds LLC acquired a new stake in IRIDEX during the first quarter worth about $46,000. Stifel Financial Corp purchased a new stake in shares of IRIDEX in the fourth quarter worth about $66,000. LPL Financial LLC purchased a new stake in shares of IRIDEX in the second quarter worth about $82,000. FineMark National Bank & Trust boosted its position in shares of IRIDEX by 27.5% in the first quarter. FineMark National Bank & Trust now owns 39,365 shares of the medical equipment provider’s stock worth $180,000 after buying an additional 8,500 shares during the period. Finally, BlackRock Inc. boosted its position in shares of IRIDEX by 117.9% in the fourth quarter. BlackRock Inc. now owns 81,249 shares of the medical equipment provider’s stock worth $382,000 after buying an additional 43,962 shares during the period. Institutional investors own 44.85% of the company’s stock.

NASDAQ:IRIX traded down $0.04 on Wednesday, hitting $2.78. 26,400 shares of the stock were exchanged, compared to its average volume of 23,275. The stock has a market capitalization of $36.78 million, a PE ratio of -2.56 and a beta of 0.82. The company has a debt-to-equity ratio of 0.10, a quick ratio of 2.49 and a current ratio of 3.41. The business has a fifty day moving average of $3.77. IRIDEX has a fifty-two week low of $2.49 and a fifty-two week high of $9.48.

About IRIDEX

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. The company offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser systems, which are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.

Featured Story: SEC Filing

Get a free copy of the Zacks research report on IRIDEX (IRIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for IRIDEX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRIDEX and related companies with MarketBeat.com's FREE daily email newsletter.